A Regulatory Perspective on Biosimilar Medicines

Marta Agostinho Cordeiro,Carla Vitorino,Carlos Sinogas,João J. Sousa

DOI: https://doi.org/10.3390/pharmaceutics16030321

IF: 6.525

2024-02-26

Pharmaceutics

Abstract:By definition, biosimilar medicinal products are biological medicinal products that are similar to other biological medicinal products that are already on the market—the reference medicinal products. Access to biosimilar medicines is a current reality. However, to achieve this goal, it is extremely important to consistently and scientifically substantiate the regulatory requirements necessary for biosimilar medicines when accessing the market. Based on an analysis of the raw materials and the type of methods used in the manufacturing processes of biological medicines, it is known that this tends to be more complex for the quality of the finished product than the manufacture of molecules obtained through a chemical process. It is then relevant to highlight the main differences between both products: biological medicines manufactured using biotechnology and the current generics containing active pharmaceutical ingredients (APIs) obtained from synthetic processes. Once arriving at the approval process of these medicinal products, it is imperative to analyse the guidance documents and the regulatory framework that create the rules that allow these biosimilar medicinal products to come to the market. The present review aimed at documenting comparatively the specific provisions of European legislation, through the European Medicines Agency (EMA), as well as the legislation of the United States of America, through the Food and Drug Administration (FDA). This was then translated into a critical appraisal of what concerns the specific criteria that determine the favourable evaluation of a biosimilar when an application for marketing authorisation is submitted to different regulatory agencies. The gathered evidence suggests that the key to the success of biosimilar medicines lies in a more rigorous and universal regulation as well as a greater knowledge, acceptance, and awareness of health professionals to enable more patients to be treated with biological strategies at an earlier stage of the disease and with more affordable medicines, ensuring always the safety and efficacy of those medicines.

pharmacology & pharmacy

What problem does this paper attempt to address?

The paper aims to address the regulatory requirements faced by biosimilar medicines during market access. Specifically, the paper emphasizes the main differences between biological medicines and chemically synthesized medicines by analyzing the types of methods used in raw materials and manufacturing processes. It also discusses in detail the approval process for biosimilars and the related guidance documents and regulatory frameworks. These regulatory frameworks are established by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

The main objectives of the paper include:
1. **Comparing EU and US regulations**: A detailed comparison of the specific regulations for biosimilars in Europe and the United States, including their respective legislative backgrounds and approval processes.
2. **Evaluating similarity standards**: Discussing the key standards for determining whether biosimilars meet market access requirements, particularly in terms of quality and safety assessments.
3. **Raising awareness of biosimilars**: Emphasizing the importance of increasing awareness and acceptance of biosimilars among healthcare professionals to ensure that more patients can access biological treatment strategies early and obtain more affordable medications while ensuring the safety and efficacy of the drugs.

Through this research, the paper hopes to promote stricter and more widespread regulation in the field of biosimilars, as well as to enhance the understanding and trust of healthcare professionals and the public in biosimilars.